VISION
DECARBONIZATION
ELECTRIFICATION
GRID RESILIENCY
WHAT
UNITING MARKETS AND TECHNOLOGIES
SERVICES
INSPIRE
EXPLORE
DEPLOY
SCALE
VALUE LEVERS
Global Network of corporates and start-ups
Testing Infrastructure Laboratory and real scale
Strategic investment and accelerator
NEWS
How waste CO2 is helping to turn renewable energy into liquid fuel
Our director David Cuesta is interviewed by Horizon, the EU Research & Innovation Magazine, to support a recent research into industrial symbiosis, clean energy solutions and the circular […]
Webinar: how the energy companies embrace the Corp. Venturing in the Energy Transition?
How is #CorporateVenturing accelerating the path towards climate neutrality? Centrica, Shell, Total, and bp discuss with everis and i-deals how a proper mix of venturing tools can accelerate new ventures to bridge the gap between net-zero ambitions […]
LATEST PROJECTS
FReSMe CCU in the steel industry
FReSMe project, funded by H2020 EU program, aims to demonstrate the whole process that enables the CO2 captured from the steel industry to produce methanol fuel that will be used as fuel in the ship transportation sector.
Lab2Market Acceleration Program
For a Japanese pharmaceutical company which was aiming to manufacture a novel drug internationally, i-deals carried out a project of selecting Contract Manufacturing Organizations (CMOs).
MefCO2 methanol fuel from CO2
MefCO2 is seeking to demonstrate the economic feasibility of valorising captured CO2 by turning it into a versatile platform chemical and renewable fuel such as methanol using hydrogen produced from renewable energy surplus.
everis Foundation
everis Foundation is one of the Spanish pioneers on rewarding entrepreneurship initiatives after XVI editions.
Opportunity Assessments
We have mainly collaborated with energy sectors through the project scheme based on the governmental organization, though there have been some projects dealt with different sectors.
Starter 2018 Acceleration Program
For a Japanese pharmaceutical company to the manufacture a novel drug, various Contract Manufacturing Organizations (CMOs) have been contracted for the current project.
